$150 million acquisition loan finalized! Shanghai Bank empowers medical and science enterprises for cross-border integration

(Source: The Paper)

Recently, a $150 million cross-border M&A loan issued by Shanghai Pudong Development Bank was successfully disbursed, strongly facilitating the strategic integration between local high-end medical device companies CNS Therapeutics and Wobi Medical; and, through a coordinated model of “M&A loans + investment funds,” helping Wobi complete major debt restructuring and optimize its capital structure, as it prepares for an overseas listing to achieve a crucial leap forward.

This also marks a strategic upgrade of Shanghai Pudong Development Bank’s technology finance service model—from a single lending deployment approach to an innovation ecosystem empowerment model as a “financial partner.”

Wobi Medical was founded in 2015. It is a global innovative medical company focused on stroke treatment technologies. In the early stage of the company’s development, Shanghai Pudong Development Bank provided credit support, accompanying the company during a high-gloss period as it completed its layout in the Europe and the United States and moved into rapid expansion.

However, the path of technological innovation is full of twists and turns. Since 2023, as changes in the external environment took effect, Wobi Medical has faced external pressure from valuation pullbacks and tighter financing in the medical device industry, while internally it has encountered challenges from complex debt issues, and some financial institutions have chosen to reduce exposure.

“Based on our deep assessment of the neurointervention segment and our continuous tracking of the company’s core technology innovation and efforts to expand overseas markets, we chose to ‘press forward against the trend’ and significantly increase the credit support. We became Wobi Medical’s largest credit-granting lender during the period of industry volatility,” said Zhong Xiaofeng, project head of Shanghai Pudong Development Bank.

Shanghai Pudong Development Bank deeply understands that technology companies need not only capital, but also comprehensive resource support. Therefore, while helping Wobi Medical address its working-capital needs for production and operations, the bank went beyond traditional logic and proactively coordinated with the company to explore paths to shed historical debt burdens and achieve sound development, continuously connecting with investment institutions, the company’s shareholders, and the management team, and jointly planning the arrival of “spring.”

As external capital markets recover, the Hong Kong-listed biotech and pharmaceuticals sector shows signs of revival, and Shanghai Pudong Development Bank keenly captured the turnaround opportunity in the company’s development.

Based on long-term tracking of the company’s performance and in-depth research into the industry, the bank gained a profound insight that Wobi Medical, as one of the few domestic neurointerventional device companies with the vast majority of its revenue coming from high-end markets such as Europe and the United States, possesses clear technological value, overseas-expansion platform value, and scarce strategic value. Shanghai Pudong Development Bank and its shareholders jointly devised the innovative plan of “M&A loans + investment fund.”

Unlike a fund acquiring 100% equity, this plan provides relatively low-cost bank leverage, which can not only help the company resolve a debt crisis and optimize its capital structure, but also—through structured design of the M&A transaction structure—provide more operating funds for the company’s global development. However, because this M&A target involves multiple countries’ legal jurisdictions, decentralized shareholder governance, and an extremely complex framework, some investment funds expressed reservations about the feasibility of the bank’s involvement in the deal. Ultimately, though, Shanghai Pudong Development Bank quickly delivered a satisfactory answer thanks to its strong professional capabilities.

“After experiencing this restructuring, I was deeply moved by Shanghai Pudong Development Bank’s professionalism, efficiency, and human warmth. They dare to innovate and break the deadlock; they are willing to lend a helping hand when it’s snowing hardest. They raise the company’s growth at critical moments. We believe this caring and responsible financial force from Shanghai Pudong Development Bank will continue to empower more local enterprises to go steady and reach far,” said Yu Jie, CFO of Wobi Medical.

The disbursement of this M&A loan is not the end of the service, but a new starting point for Shanghai Pudong Development Bank’s full-lifecycle financial companionship with the company. Next, leveraging the advantages of the FT account system for efficient cross-border fund settlement and low foreign-exchange conversion costs, Shanghai Pudong Development Bank will help Wobi Medical optimize global working-capital management. At the same time, adhering to a “invest-and-lend in coordination” mindset, it will continue to follow up on the company’s next round of financing and its IPO process, providing full-process financial support.

Original headline: “$150 million M&A loan completed! Shanghai Pudong Development Bank empowers cross-border integration for medical enterprises”

Column editor-in-chief: Rong Bing

Source: Author: Wenhui Daily, Tang Weijie

A wealth of information and precise interpretation—available in the Sina Finance app